ATE303144T1 - Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge - Google Patents

Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge

Info

Publication number
ATE303144T1
ATE303144T1 AT96939542T AT96939542T ATE303144T1 AT E303144 T1 ATE303144 T1 AT E303144T1 AT 96939542 T AT96939542 T AT 96939542T AT 96939542 T AT96939542 T AT 96939542T AT E303144 T1 ATE303144 T1 AT E303144T1
Authority
AT
Austria
Prior art keywords
reduce
weight loss
complications
reduction
fatty acid
Prior art date
Application number
AT96939542T
Other languages
English (en)
Inventor
Francis P Kuhajda
Gary R Pasternack
Craig A Townsend
Neelakandha S Mani
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE303144T1 publication Critical patent/ATE303144T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96939542T 1995-11-17 1996-11-15 Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge ATE303144T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US694095P 1995-11-17 1995-11-17
PCT/US1996/017678 WO1997018806A1 (en) 1995-11-17 1996-11-15 Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Publications (1)

Publication Number Publication Date
ATE303144T1 true ATE303144T1 (de) 2005-09-15

Family

ID=21723376

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939542T ATE303144T1 (de) 1995-11-17 1996-11-15 Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge

Country Status (7)

Country Link
EP (1) EP0869784B1 (de)
AT (1) ATE303144T1 (de)
AU (1) AU7668596A (de)
DE (1) DE69635130T2 (de)
DK (1) DK0869784T3 (de)
ES (1) ES2251002T3 (de)
WO (1) WO1997018806A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
MXPA03011554A (es) 2001-06-13 2004-10-28 Magnachem Int Lab Inc Formulaciones de lactona y metodos de uso.
BRPI0312413A2 (pt) * 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
WO2005102315A1 (en) 2004-04-23 2005-11-03 Magnachem International Laboratories, Inc. Synthetic lactone formulations for pain control
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2010048616A2 (en) 2008-10-24 2010-04-29 Magnachem International Laboratories, Inc. Method for screening for compounds selectively interacting with rad9
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028397A (en) * 1973-07-05 1977-06-07 Hoffmann-La Roche Inc. Hydroxycitric acid derivatives
US4218443A (en) * 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
JP2746372B2 (ja) * 1988-03-11 1998-05-06 科研製薬株式会社 Ｆ−０３６８物質
US5447954A (en) * 1992-05-05 1995-09-05 Smithkline Beecham P.L.C. Phenylderivate as inhibitors of ATP citrate lyase
WO1994002108A1 (en) * 1992-07-24 1994-02-03 The Johns Hopkins University Chemotherapy for cancer

Also Published As

Publication number Publication date
EP0869784B1 (de) 2005-08-31
WO1997018806A1 (en) 1997-05-29
AU7668596A (en) 1997-06-11
EP0869784A4 (de) 2001-02-07
EP0869784A1 (de) 1998-10-14
DE69635130D1 (de) 2005-10-06
ES2251002T3 (es) 2006-04-16
DK0869784T3 (da) 2006-01-16
DE69635130T2 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
Morrow et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation.
Reiterer et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor–deficient mice
Chvapil Pharmacology of fibrosis: definitions, limits and perspectives
ATE303144T1 (de) Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
EA200100742A1 (ru) Применение 4-h-1-бензопиран-4-оновых производных в качестве ингибиторов пролиферации клеток гладких мышц
Haynes Physiologically active unsatured lactones
Shih et al. Concentration-dependent differential effects of quercetin on rat aortic smooth muscle cells
NZ513328A (en) Cardiovascular and bone treatment composition comprising formononetin and one or more other isoflavone
Carmeli et al. Effect of growth hormone on gastrocnemius muscle of aged rats after immobilization: biochemistry and morphology
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
Nyska et al. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery
AU6667001A (en) Novel heterocyclic analogs of diphenylethylene compounds
Müller Expression of c-fos in quiescent Swiss 3T3 cells exposed to aqueous cigarette smoke fractions
ATE281831T1 (de) Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
Auyong et al. Pharmacological aspects of juglone
NL8103594A (nl) Cosmetisch middel met huid- en spierherstellende werking en een werkwijze voor de bereiding ervan.
Turner Garlic and circulatory disorders
Soengas et al. Effects of cortisol and thyroid hormone treatment on the glycogen metabolism of selected tissues of domesticated rainbow trout, Oncorhynchus mykiss
Aellig et al. Is the ISA of pindolol beta 2‐adrenoceptor selective?
Hirose et al. Reduced ischemia-reperfusion injury in muscle Experiments in rats with EPC-K1, a new radical scavenger
Irving et al. Bone formation in normal and vitamin D-treated rachitic rats during the administration of polyphosphates.
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
YOUNG Evaluation of four purine compounds in poultry products
ROBERT Complete prevention of cerebral accidents in malignant hypertension
DE69805445D1 (de) Matthiolasamen öl, dieses enthaltende zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0869784

Country of ref document: EP

REN Ceased due to non-payment of the annual fee